Mutations in Noncoding Regions of Human Genome Also Cause Cancer, Study Shows
While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in the noncoding regions of our…
News
Advanced Myeloma Patients Responding to Selinexor Plus Standard Therapies in Trial, Data Show
Updated clinical trial data show that selinexor added to standard therapies can benefit multiple myeloma patients who have failed multiple prior lines of therapy, Karyopharm…
Trillium Doses First Patient with TTI-622, a Candidate for Treating Myeloma, Lymphoma
Trillium Therapeutics recently dosed the first patient in its Phase 1 clinical trial of TTI-622, a checkpoint inhibitor of the immune system being developed…
Companies Collaborating to Use ClonoSEQ Assay in Multiple Myeloma Trials Testing Isatuximab
Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients receiving isatuximab, a treatment…
Clinical Trial of Potential CAR T-cell Therapy for Advanced Multiple Myeloma to Open in US
Janssen recently initiated a Phase 1b/2 clinical development program to evaluate JNJ-68284528, a chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment  of…
Amgen, MD Anderson Collaborate to Advance Early-stage Treatments for Myeloma, Other Cancers
Two multi-year collaborative agreements were recently established by Amgen and the University of Texas MD Anderson Cancer Center to advance the development of…
Aplidin-Dexamethasone Combo Improves Survival in Advanced Multiple Myeloma Patients, Phase 3 Trial Reports
Combining Aplidin (plitidepsin) with dexamethasone significantly extends their survival in heavily pretreated multiple myeloma patients compared to dexamethasone alone, data from a Phase 3 trial…
Most in U.S. are Unaware of Recent Shortages of Cancer Therapies, Survey Says
Most U.S. residents are unaware there are shortages in the availability of cancer drugs, such as those for multiple myeloma, a type of cancer…
Tilsotolimod and Yervoy Combo Seen to Shrink Tumors in Pre-treated Metastatic Melanoma Patients in Ongoing Phase 2 Trial
A combination of Idera Pharmaceuticals’s treatment candidate tilsotolimod plus Yervoy (ipilimumab) is able to reduce tumors in a group of patients with refractory…
Pomalyst Triple Combo Delays Disease Progression in Relapsed or Refractory Myeloma Patients, Phase 3 Data Show
Adding Pomalyst (pomalidomide) to a combination of Velcade (bortezomib) and dexamethasone significantly extended…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML